Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation (original) (raw)
Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain
Luisa Martinez-pomares
Journal of Allergy and Clinical Immunology, 2012
View PDFchevron_right
Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG
Roseline d'Oiron
View PDFchevron_right
Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors
Kanjaksha Ghosh
Clinical Reviews in Allergy Immunology, 2009
View PDFchevron_right
Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells
B. Wootla
Haemophilia, 2007
View PDFchevron_right
Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells Reply
Jan Voorberg
The Journal of Allergy and Clinical Immunology, 2012
View PDFchevron_right
Quantitative HLA‐class‐II/Factor VIII (FVIII) Peptidomic Variation in Dendritic Cells Correlates with the Immunogenic Potential of Therapeutic FVIII Proteins in Hemophilia A
Huy Huynh
Journal of Thrombosis and Haemostasis
View PDFchevron_right
Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A
Ana Navarrete
Journal of Thrombosis and Haemostasis, 2009
View PDFchevron_right
Enhanced uptake of blood coagulation factorVIIIcontaining immune complexes by antigen presenting cells
Edith Slot
Journal of Thrombosis and Haemostasis, 2017
View PDFchevron_right
Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic …
Roseline d'Oiron
…, 2004
View PDFchevron_right
Factor VIII Hemophilia A Inactivate Therapeutic Catalytic IgG from Patients with
Johan Hoebeke
2000
View PDFchevron_right
Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development
Roseline d'Oiron
2010
View PDFchevron_right
Inhibitors in haemophilia A: the role of VWF/FVIII concentrates - a meeting report
Alessandro Gringeri
Haemophilia, 2009
View PDFchevron_right
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
International Journal of Molecular and Cellular Medicine
International Journal of Molecular and Cellular Medicine (IJMCM), 2020
View PDFchevron_right
Dangerous liaisons: how the immune system deals with factor VIII
Jan Voorberg, Aleksandra Wroblewska
Journal of Thrombosis and Haemostasis
View PDFchevron_right
Immune Complexes Enhance Uptake of Blood Coagulation Factor VIII by Antigen Presenting Cells
Jan Voorberg
Blood, 2012
View PDFchevron_right
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice
Aleksandra Wroblewska
Blood, 2012
View PDFchevron_right
Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity
Hartmut Weiler
Blood, 2008
View PDFchevron_right
Alloantibodies to factor VIII in haemophilia
Saulius Butenas
Haemophilia, 2011
View PDFchevron_right
Intravenous administration of Factor VIII–O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein
Sathy Balu-iyer
European Journal of Pharmaceutical Sciences, 2015
View PDFchevron_right
Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients
Jack Spira
British Journal of Haematology, 2012
View PDFchevron_right
Immunogenicity of Current and New Therapies for Hemophilia A
Alessandra Prezotti
Pharmaceuticals
View PDFchevron_right
Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells
M. Ozelo
Journal of Thrombosis and Haemostasis, 2008
View PDFchevron_right
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity
Julie Tarrant
Blood, 2017
View PDFchevron_right
Alloantibodies to therapeutic factor VIII in hemophilia A the role of
Blanca Salazar
View PDFchevron_right
Transplantation of endothelial cells corrects the phenotype in hemophilia A mice
Antonia Follenzi
2005
View PDFchevron_right
Use of recombinant factor VIII in the management of hemophilia
marco cattaneo
Current studies in hematology and blood transfusion, 1991
View PDFchevron_right
IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A
Gestur Vidarsson
British Journal of Haematology, 2008
View PDFchevron_right
Immune tolerance induction in haemophiliacs with inhibitor to FVIII: high- or low-dose programme
Tomasz Nowak
Haemophilia, 1996
View PDFchevron_right